Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. (2020)
Attributed to:
The Future Vaccine Manufacturing Research Hub (Vax-Hub)
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)31604-4
PubMed Identifier: 32702298
Publication URI: http://europepmc.org/abstract/MED/32702298
Type: Journal Article/Review
Volume: 396
Parent Publication: Lancet (London, England)
Issue: 10249
ISSN: 0140-6736